Posts by Kenneth Encarnacion
11
Apr
Randall W. Jones, D.Eng. (PhD, MBA)
EARLY DETECTION through Screening
Population-Based Screening Studies
Screening for Prostate Canc...
18
Mar
ConcertAI’s TeraRecon and Bot Image, Inc. Partnership
TeraRecon, on March 18, 2023
CAMBRIDGE, Mass., Mar. 18,2023 /PRNewswire/ -- The Eureka Clinical AI platform, from ConcertAI's Tera...
22
Feb
Prostate Cancer Treatment can be safely delayed and inexpensively and accurately monitored thanks to AI
Bot Image, Inc., a Nebraska and Maine based Artificial Intelligence medical device company, has received FDA-clearance on its ProstatID...
22
Feb
ProstatID kick-starts your Prostate MRI program
ProstatID, THE AI software FDA-cleared for not only detection and diagnosis of PCa, but also for screening using bpMRI. Yes, ‘screeni...
13
Feb
New Studies Demonstrate that Bot Image’s Prostate Cancer AI Software Outperforms the Field
Bot Image, Inc., a Nebraska and Maine based Artificial Intelligence medical device company (www.botimageai.com), raised the performance...
13
Feb
Bot Image highlights performance of ProstatID in study
AI medical device company Bot Image is highlighting the performance of its ProstatID in a study evaluating its ability to detect, diagnose, and screen for prostate cancer.
21
Aug
Successful Beta Test
We’re proud to announce that in partnership with our beta testing site, we processed our first test case using the cloud-based architecture on 6/18/2020.
19
Aug
ProstatID Passes FDA 510(k) Administrative Review
The Bot Image team has been hard at work trying to obtain FDA clearance. We’re excited to announce that we have passed the first major milestone on July 21, 2020.
12
Nov
Bot Image On Trial Site News
Trial Site News features the latest coverage of clinical research. Read the article here: